Reg. name: Dacogen
Class: Hypomethylating agent
It has been demonstrated that decitabine (Dacogen®) can cause DNA demethylation by inactivation of DNA Methyltransferase-1 (DNMT-1), the enzyme responsible for methylation of the DNA. The inhibition of this enzyme leads to in-gene promoter hypomethylation that can result in reactivation of tumour suppressor genes, inducing cellular differentiation or cellular senescence followed by programmed cell death.
- Dacogen® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/27127. [Accessed January 2017].
DACOGEN® is indicated for the treatment of adult patients with newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy
Reg. name: Idhifa®
Class: IDH2 inhibitor
Enasidenib is an oral, selective inhibitor of mutated Isocitrate Dehydrogenase 2 (IDH2). Enasidenib binds and inhibits the mutant IDH2 enzyme that is responsible for the accumulation of 2-Hydroxyglutarate (2-HG).
- Mondesir J, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives J Blood Med. 2016; 7: 171–180.
IDHIFA® is indicated for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an Isocitrate Dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.